Updates are available Correction dated 2020-07-07
Click to view Correction: https://doi.org/10.1038/s41590-020-0752-z
-
Authors
Akassoglou, Katerina http://orcid.org/0000-0002-2632-1465
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS097976)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG064926)
U.S. Department of Defense (MS160082)
- License Information
-
More Information
Article History
First Online: 23 June 2020
Change Date: 7 July 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-020-0752-z
Competing interests
: K.A. is the scientific founder and advisor of Therini Bio, Inc. K.A. is an inventor on The Regents of the University of California issued patents US7807645, US8569242, US8877195 and US8980836 covering fibrin antibodies; a co-inventor on The Regents of the University of California and Gladstone Institutes pending patent applications U.S. 15/943,474 and EP 15735033.1 covering fibrin assays of microglia activation; and a co-inventor on Gladstone Institutes issued patent US9669112 covering fibrin in vivo models and US10451611 and pending patent applications U.S. 16/572,365 and EP 15735284.05 covering in vitro fibrin assays. Her interests are managed in accordance with the Gladstone Institutes’ conflict of interest policy.
